Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab
Activating RAS mutations occur in more than a half of colorectal cancers (CRCs). RAS-mutated CRCs are notoriously difficult to treat given that they are characterized by the aggressive disease course and the lack of appropriate targeted therapies. Recent preclinical studies demonstrated that RAS-mut...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2020-08-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/509241 |
| _version_ | 1818387848615690240 |
|---|---|
| author | Sergey V. Orlov Magaripa A. Urtenova Maria A. Sviridenko Denis V. Nesterov Tatiana N. Sokolova Evgeny N. Imyanitov |
| author_facet | Sergey V. Orlov Magaripa A. Urtenova Maria A. Sviridenko Denis V. Nesterov Tatiana N. Sokolova Evgeny N. Imyanitov |
| author_sort | Sergey V. Orlov |
| collection | DOAJ |
| description | Activating RAS mutations occur in more than a half of colorectal cancers (CRCs). RAS-mutated CRCs are notoriously difficult to treat given that they are characterized by the aggressive disease course and the lack of appropriate targeted therapies. Recent preclinical studies demonstrated that RAS-mutated cells escape from therapeutic MEK inhibition by the development of autophagy, and this escape may be prevented by the administration of an antimalarial drug, hydroxychloroquine. The available clinical data are limited to a single case observation involving a patient with KRAS-mutated pancreatic cancer. Here, we report a woman with KRAS G12D-mutated CRC, whose tumor did not respond to conventional therapy. The combination of binimetinib, hydroxychloroquine, and bevacizumab was administered as a last-hope option. The patient experienced rapid improvement of the performance status. The tumor lumps demonstrated 17% reduction in the size within the first 6 weeks of the therapy. This report calls for evaluation of the efficacy of a combination of MEK inhibitors and hydroxychloroquine, possibly with the addition of bevacizumab, in chemotherapy-resistant patients with RAS-mutated cancers. |
| first_indexed | 2024-12-14T04:16:28Z |
| format | Article |
| id | doaj.art-7c1eed8c564649b0b17db2a565354f31 |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-14T04:16:28Z |
| publishDate | 2020-08-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-7c1eed8c564649b0b17db2a565354f312022-12-21T23:17:31ZengKarger PublishersCase Reports in Oncology1662-65752020-08-0113298598910.1159/000509241509241Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and BevacizumabSergey V. OrlovMagaripa A. UrtenovaMaria A. SviridenkoDenis V. NesterovTatiana N. SokolovaEvgeny N. ImyanitovActivating RAS mutations occur in more than a half of colorectal cancers (CRCs). RAS-mutated CRCs are notoriously difficult to treat given that they are characterized by the aggressive disease course and the lack of appropriate targeted therapies. Recent preclinical studies demonstrated that RAS-mutated cells escape from therapeutic MEK inhibition by the development of autophagy, and this escape may be prevented by the administration of an antimalarial drug, hydroxychloroquine. The available clinical data are limited to a single case observation involving a patient with KRAS-mutated pancreatic cancer. Here, we report a woman with KRAS G12D-mutated CRC, whose tumor did not respond to conventional therapy. The combination of binimetinib, hydroxychloroquine, and bevacizumab was administered as a last-hope option. The patient experienced rapid improvement of the performance status. The tumor lumps demonstrated 17% reduction in the size within the first 6 weeks of the therapy. This report calls for evaluation of the efficacy of a combination of MEK inhibitors and hydroxychloroquine, possibly with the addition of bevacizumab, in chemotherapy-resistant patients with RAS-mutated cancers.https://www.karger.com/Article/FullText/509241colorectal cancerkras mutationbinimetinibhydroxychloroquinebevacizumab |
| spellingShingle | Sergey V. Orlov Magaripa A. Urtenova Maria A. Sviridenko Denis V. Nesterov Tatiana N. Sokolova Evgeny N. Imyanitov Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab Case Reports in Oncology colorectal cancer kras mutation binimetinib hydroxychloroquine bevacizumab |
| title | Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab |
| title_full | Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab |
| title_fullStr | Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab |
| title_full_unstemmed | Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab |
| title_short | Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab |
| title_sort | rapid improvement of the performance status and reduction of the tumor size in kras mutated colorectal cancer patient receiving binimetinib hydroxychloroquine and bevacizumab |
| topic | colorectal cancer kras mutation binimetinib hydroxychloroquine bevacizumab |
| url | https://www.karger.com/Article/FullText/509241 |
| work_keys_str_mv | AT sergeyvorlov rapidimprovementoftheperformancestatusandreductionofthetumorsizeinkrasmutatedcolorectalcancerpatientreceivingbinimetinibhydroxychloroquineandbevacizumab AT magaripaaurtenova rapidimprovementoftheperformancestatusandreductionofthetumorsizeinkrasmutatedcolorectalcancerpatientreceivingbinimetinibhydroxychloroquineandbevacizumab AT mariaasviridenko rapidimprovementoftheperformancestatusandreductionofthetumorsizeinkrasmutatedcolorectalcancerpatientreceivingbinimetinibhydroxychloroquineandbevacizumab AT denisvnesterov rapidimprovementoftheperformancestatusandreductionofthetumorsizeinkrasmutatedcolorectalcancerpatientreceivingbinimetinibhydroxychloroquineandbevacizumab AT tatianansokolova rapidimprovementoftheperformancestatusandreductionofthetumorsizeinkrasmutatedcolorectalcancerpatientreceivingbinimetinibhydroxychloroquineandbevacizumab AT evgenynimyanitov rapidimprovementoftheperformancestatusandreductionofthetumorsizeinkrasmutatedcolorectalcancerpatientreceivingbinimetinibhydroxychloroquineandbevacizumab |